Filing Flows › Tvardi Therapeutics (TVRD) › Q4 2024 › vs Q4 2023
Tvardi Therapeutics (TVRD) Q4 2024 vs Q4 2023 (year over year)
Tvardi Therapeutics's revenue fell $1.5M (-52%) from $3.0M in Q4 2023 to $1.5M in Q4 2024.
Tvardi Therapeutics, Q4 2024: revenue $1.5M (-52% year over year), operating margin -372.7%, net loss $7.7M, operating cash flow −$4.0M. The chart draws each line against Q4 2023, the increases inside each band.
Every line
| Line | Q4 2024 | Q4 2023 | Change | % |
|---|---|---|---|---|
| Revenue | $1.5M | $3.0M | −$1.5M | -52% |
| Income tax benefit | $398K | $0 | $398K | — |
| Net loss | $7.7M | $32.3M | −$24.7M | -76% |
| Costs & expenses | $9.5M | $35.6M | −$26.1M | -73% |
| Operating costs | $6.9M | $35.6M | −$28.7M | -81% |
| Interest & other, net | $2.7M | −$270K | $2.9M | — |
| Operating cash sources | $7.7M | $32.3M | −$24.6M | -76% |
| Share-based compensation | $2.4M | $3.6M | −$1.2M | -35% |
| Working capital & other | $1.3M | $11.3M | −$10.0M | -89% |
| Cash used in operations | $4.0M | $17.4M | −$13.3M | -77% |
| Net loss absorbed | $7.7M | $32.3M | −$24.7M | -76% |
Questions
How much did Tvardi Therapeutics's revenue grow year over year in Q4 2024?
Tvardi Therapeutics's revenue fell $1.5M (-52%) from $3.0M in Q4 2023 to $1.5M in Q4 2024.